X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
PLX-4545 is an IKZF2 Inhibitor, small molecule drug candidate, which is currently being evaluated for the treatment of patients suffering from solid tumors.
Lead Product(s): PLX-4545
Therapeutic Area: Oncology Product Name: PLX-4545
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 12, 2023
Details:
Under the terms of the collaboration, Plexium will conduct preclinical research activities for the collaboration targets, after which AbbVie has the option to select programs for additional research and development activities.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Small molecule
Partner/Sponsor/Collaborator: AbbVie Inc
Deal Size: $565.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration April 28, 2022
Details:
The proceeds from the financing will enable Plexium to accelerate its pipeline programs toward the clinic, including a molecular glue that selectively degrades the IKZF2 transcription factor, selective degraders of CDK2 and SMARCA2, and other undisclosed high value targets.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: BVF Partners
Deal Size: $102.0 million Upfront Cash: Undisclosed
Deal Type: Financing February 23, 2022
Details:
Under the terms of the agreement, the collaboration will initially focus on two programs with Amgen holding options to add additional programs. Amgen has a commercial license to each program that advances to a preclinical stage of development and commercialization.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Small molecule
Partner/Sponsor/Collaborator: Amgen Inc
Deal Size: $500.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration February 03, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
